Drug Farm to Present Phase 1b Clinical Data of DF-006, a First-in-Class Oral ALPK1 Agonist for Chronic Hepatitis B, at EASL 2024 Late-Breaking Poster Session

May 06, 2024 16:33 CST Updated 16:33

Drug Farm

Innovative Therapies Researcher for Infectious and Immune Diseases

Haoyue Values

MissionEmpower with Capital, Build an Excellent Healthcare Enterprise

VisionTo become the most outstanding investment bank in China's healthcare industry

HaoYue Capital, founded in January 2014, is a leading investment bank in China that focuses on the healthcare industry. Headquartered in Shanghai, the company has regional offices in Beijing, Shenzhen, and Hong Kong. HaoYue Capital is committed to leveraging capital and research-driven insights to help outstanding enterprises in China's healthcare sector successfully access the capital markets and create added value for clients. The partnership team at HaoYue Capital consists of senior investment bankers with years of deep engagement in China’s healthcare industry. HaoYue Capital consistently tracks developments and investment trends in the healthcare market, covering innovative pharmaceuticals, cutting-edge medical devices, IVD and life sciences, health services, and smart healthcare. As of 2023, HaoYue Capital has completed nearly 400 projects with a total transaction value exceeding tens of billions of US dollars; including over 50 mergers and acquisitions deals totaling more than 50 billion US dollars. In 2023, HaoYue Capital executed close to 50 private equity financings, mergers and acquisitions, and complex spin-off transactions from listed companies, with a total transaction value amounting to several billion US dollars, maintaining its comprehensive leadership across various sub-sectors of the healthcare industry.

Recently, Drug Farm announced that itsIndependently DevelopedALPK1 AgonistDF-006ImmunomodulatorTreatmentPatients with Chronic Hepatitis BTheData from the Phase 1b study DF-006-1001 will be presented as a "late breaking poster presentation" at the 2024 European Association for the Study of the Liver (EASL) Congress. The 2024 EASL Congress will take place from June 5 to 8 in Milan, Italy.

Drug Farm is a biotechnology company dedicated to the discovery of targets and the development of "first-in-class" drugs.Focusing on the development of treatments for hepatitis B, cancer, heart and kidney diseases, as well as ROSAH syndrome, etc.Autoimmune DiseaseInnovative Therapy。It is reported that the company'sIDInVivo+ Platform Combines Breakthrough Technologies in Genetics and Artificial Intelligence to Discover New Treatments, Enabling Direct Selection of Gene Targets in Immunocompetent Animal Models. Using the IDInVivo+ platform, Drug Farm has discovered multiple novel innate immune pathways and targets, and is rapidly advancing several original drugs into clinical development.

DF-006 isA Drug Farm DevelopmentPotential "first-in-class"ALPK1 Agonist Immunomodulator, which can effectively stimulate local innate immunity in the liver. DF-006 has successfully completed single and multiple ascending dose evaluations in healthy volunteers and in virologically suppressed HBeAg-negative chronic hepatitis B (CHB) Multiple incremental dose assessments were completed in patients.

"There is currently no effective cure for chronic hepatitis B. DF-006 has a new mechanism of action that can stimulate the body's own immune system to help clear the infection. As an oral medication administered once a week, DF-006 has the potential to become the preferred immunomodulator in combination therapy for HBV," commented Dr. Ed Gane, Professor of Medicine at the University of Auckland, Chief Hepatologist at Auckland Hospital, transplant physician, and Deputy Director of the New Zealand Liver Transplant Unit.

"DF-006 has demonstrated effective preclinical anti-HBV responses, including the inhibition of covalently closed circular DNA (cccDNA) and T-cell recruitment. The data from this Phase 1b study providesDF-006"Provided clinical support, this drug can be used to help cure CHB patients."Drug FarmChiefMedical OfficerDr. Jeysen Yogaratnam said.

Contact Us

Shanghai Office

Room 2302, Qiantan Center, No. 555 Haiyang West Road, Pudong New Area, Shanghai, China

Rm 2302, New Bund Center, 555 West Haiyang Rd, Pudong New Area, Shanghai

Beijing Office

Room 3608, Taikang Financial Tower, Building 1, Yard 38, North Third Ring Road, Chaoyang District, Beijing, China

3608, Taikang Financial Building, Building 1, Yard 38, North Rd of East 3rd Ring, Chaoyang District

Shenzhen Office

Room 25J, Building A, NEO Tower, No. 6011 Shennan Avenue, Futian District

J, 25F, Tower A, NEO Building, 6011 Shennan Avenue, Futian District, Shenzhen

Hong Kong Office

10th Floor, Manulife Plaza, 33 Lockhart Road, Wanchai District

10th Floor, YF Life Tower, 33 Lockhart Road, Wan Chai, Hong Kong

Project Delivery

info@healthcarecapital.com.cn

媒体问询 Media inquiries

pr@healthcarecapital.com.cn

Recruitment

hr@healthcarecapital.com.cn